search
Back to results

Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.

Primary Purpose

Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Liver Fibroses

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
LIVERFASt
Sponsored by
Fibronostics USA, Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Non-Alcoholic Fatty Liver Disease focused on measuring LIVERFASt, Liver biopsy, Liver Fibrosis, Liver Activity, Liver Steatosis, Non-invasive serum biomarker, Neural Network, Artificial Intelligence Machine Learning, Algorithm based test

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • • Consenting patients with suspected NAFLD (by any means) having had undergone liver biopsy as part as their routine management, simultaneously or within six months from the day of blood sampling for LIVERFAStTM test.

    • Aged 18 to 80 years old, inclusive
    • Male or Female from any ethnicity
    • Willing to undergo blood sampling for LIVERFAStTM testing after 6 to 12 hours fasting
    • Willing to allow histological lecture by a pathologist for NASH-CRN and SAF scoring systems analysis of the liver biopsy
    • Willing and able to allow access to requested data and who were informed and signed the consent form.

Exclusion Criteria:

  • • Inability to provide informed consent

    • Patients who may be uncooperative with the sample collection procedures
    • History of known Severe coagulopathy
    • History of known Hepatic abscess
    • Renal failure undergoing dialysis (GFR<45)
    • History of Malignancy in the past 2 years
    • Previous liver transplantation
    • Suffering with a terminal illness or any other conditions or diseases that the investigator considers inappropriate for study participation
    • Secondary causes of hepatic fat accumulation such as significant alcohol consumption, long-term use of a steatogenic medication, ()
    • Ongoing or recent significant alcohol consumption defined as >21 standard drinks on average per week in men and >14 standard drinks on average per week in women.8 Approximately 10 g of alcohol equals one 'drink' unit. One unit equals 1 ounce of distilled spirits, one 12-oz beer, or one 4-oz glass of wine.
    • Total parenteral nutrition within 3 months of interview
    • Short bowel syndrome
    • History of gastric or jejunoileal bypass preceding the diagnosis of NAFLD. Bariatric surgery performed concomitant with or following the diagnosis of NAFLD does not exclude enrollment of patients.
    • History of biliopancreatic diversion
    • Evidence of advanced liver disease defined as a Child-Pugh-Turcotte score of equal to or greater than 10
    • Evidence of chronic hepatitis B as marked by the presence of HBsAg in serum (patients with isolated antibody to hepatitis B core antigen, anti-HBc, are not excluded)
    • Evidence of chronic hepatitis C as marked by the presence of anti-HCV and HCV RNA in serum; patients with anti-HCV with PCR negative should not be excluded
    • Low alpha-1-antitrypsin level and ZZ phenotype (both determined at the discretion of the investigator)
    • History of Wilson's disease
    • Known glycogen storage disease
    • Known dysbetalipoproteinemia
    • Known phenotypic hemochromatosis (determined at the discretion of the investigator)
    • History of primary biliary cholangitis (PBC)/primary biliary sclerosis (PSC)
    • Hepatic vascular lesions (determined at the discretion of the investigator)
    • History of liver liver granulomas sarcoidosis, and infectious diseases such as tuberculosis)
    • Congenital hepatic fibrosis, polycystic liver disease
    • Other metabolic/congenital liver disease
    • Evidence of systemic infectious disease
    • Known HIV positive
    • Disseminated or advanced extrahepatic malignancy

    • Conditions that could interfere with LIVERFASt parameters and could lead to risk of false positive/ false negative results:

      1. Drug induced liver-injury (DILI), acute alcoholic hepatitis
      2. Acute inflammatory syndrome or sepsis Active drug use or dependence that, in the opinion of the study investigator, would interfere with adherence to study requirements

Sites / Locations

  • Henry Ford Health System
  • St. Louis University
  • Northwell Health, Inc
  • GCGA Physicians, LLC
  • Methodist Health System Clinical Research Institute
  • Baylor College of Medicine
  • Houston Methodist Research Institute
  • Liver Associates of Texas, P.A.

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

LIVERFASt validation

Arm Description

blood draw for LIVERFASt

Outcomes

Primary Outcome Measures

Clinical performance of LIVERFASt Tests to determine liver fibrosis scores and staging compared with Liver Biopsy in patients with presumed Non-Alcoholic Fatty Liver Disease (NAFLD).
Primary: Clinical performance of the LIVERFASt Fibrosis score using the results of five serum biomarkers (A2M, Haptoglobin, ApoA1, Total Bilrubin and GGT) for the over-all diagnostic of liver fibrosis (F0, F1, F2, F3 and F4 stages) using Binary and Non-Binary-Area Under the ROC curve
Clinical performance of LIVERFASt Tests to determine inflammatory activity scores and staging compared with Liver Biopsy in patients with presumed Non-Alcoholic Fatty Liver Disease (NAFLD).
Clinical performance of the LIVERFASt Activity scores using the results of six serum biomarkers (A2M, Haptoglobin, ApoA1, Total Bilrubin, GGT and ALT) for the over-all diagnostic of inflammatory activity (A0, A1, A2, A3 and A4 grades) using Binary and Non-Binary-Area Under the ROC curve
Clinical performance of LIVERFAStTM Tests to determine steatosis grading compared with Liver Biopsy in patients with presumed Non-Alcoholic Fatty Liver Disease (NAFLD).
Clinical performance of the LIVERFAstTM Steatosis grading tests using the results of ten serum biomarkers (A2M, Haptoglobin, ApoA1, Total Bilrubin, GGT, ALT, AST, Triglyceride, Cholesterol and Fasting Blood Glucose) for the over-all diagnostic of steatosis (S0, S1, S2 and S3), using Binary and Non-Binary-Area Under the ROC curve

Secondary Outcome Measures

Clinical performance evaluation of the LIVERFASt Tests to evaluate and measure the definition of NAFLD based on fibrosis staging (F0, F1, F2, F3 and F4), inflammatory activity (A0, A1, A2, A3 and A4) and steatosis grading (S0, S1, S2, and S3).
Secondary 200 adult men and women who are between the ages of 18-80 years old patients who have undergone liver biopsy with suspected non-alcoholic fatty liver disease within six (6) months of the enrollment and have undergone blood sampling for LIVERFASt testing using the generated results of ten serum biomarkers, namely: A2M, Haptoglobin, ApoA1, Total Bilrubin, GGT, ALT, AST, Triglyceride, Cholesterol and Fasting Blood Glucose, for the over-all diagnosis of fibrosis (F0, F1 to F4), activity (A0, A1 to A4) and steatosis (S0, S1 to S3). Performance (Bin-AUROC) of the LIVERFASt using the results of the combination of the ten biomarkers for the NAFLD definitions of NAFL, NASH and significant NASH (>S1≥A2≥F2)

Full Information

First Posted
September 25, 2020
Last Updated
July 29, 2022
Sponsor
Fibronostics USA, Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT04579874
Brief Title
Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.
Official Title
Clinical Performance Evaluation of LIVERFASt Tests to Determine Fibrosis Staging, Inflammatory Activity and Steatosis Grading Compared w/ Liver Biopsy in Patients w/ Metabolic Factors & Presumed Non-Alcoholic Fatty Liver Disease (NAFLD).
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
January 7, 2021 (Actual)
Primary Completion Date
December 15, 2021 (Actual)
Study Completion Date
April 15, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fibronostics USA, Inc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes

5. Study Description

Brief Summary
The primary objective of this study is to assess the clinical performance of LIVERFAStTM In Vitro Diagnostic (IVD) Tests (Fibrosis score, Activity score and Steatosis score) in NAFLD suspected patients for staging of fibrosis and for grading of inflammatory activity and steatosis, taking as reference the liver biopsy with histological classification of the elementary lesions determined according to SAF scores (Bedossa P., Hepatology 2012). The secondary objective is to assess the performance of LIVERFAStTM for the histological definition of NAFLD, including NAFL and NASH and severe NASH
Detailed Description
Chronic liver diseases (CLDs), such as chronic viral hepatitis, nonalcoholic fatty liver diseases (NAFLD) and nonalcoholic steatohepatitis (NASH), are a leading cause of morbidity and mortality globally and usually develops over many years. The prevalence of NAFLD has increased in recent years (15% in 2005 to 25% in 2010) mainly due to the increase prevalence of obesity and diabetes. As, approximately 20% of NAFLD cases develop NASH, the associated increase in NASH during the same period is to be expected (33% in 2005 to 59.1% in 2010). As a result, staging of liver fibrosis is essential in determining the prognosis and optimal treatment for patients with NASH. Furthermore, evaluation of fibrosis in NAFLD patients can help refine treatment options designed to prevent the progression to NASH. One recent study demonstrates significant sampling variability of routine liver biopsy in patients with NAFLD (Ratziu V. et al. Gastroenterology 2008). The diagnosis of NASH would have been missed in 35% and the discordance for steatosis grading was encountered in 22% of patients. Developing safe and easily accessible noninvasive modalities to accurately evaluate fibrosis stage of NAFLD and NASH is of utmost importance in clinical practice. Fibronostics breaks through the burden to serve patients. By empowering their providers with IVD clinical tools within the clinic, the ability to ensure screening and clinical adherence is assured, and the ease for early detection profoundly shifts the $2B economic burden. LIVERFASt is a non-invasive clinical and staging In-Vitro-Diagnostic (IVD) tool, which has been developed as an alternative to liver biopsy. LIVERFASt is a safe, and reproducible tool which provides surrogate grading and staging of the three elementary features of NASH: steatosis, inflammatory activity and fibrosis. LIVERFAStTM combines age, gender, weight and height with common liver function tests (ALT, AST, GGT, total bilirubin), lipid profile (total cholesterol, triglycerides), fasting glucose and three specific proteins of the liver with hepatoprotective functions and predictive value in NAFLD -alpha2-macroglobulin (A2M), haptoglobin (HAP) and apolipoprotein A1 (APOA1). The main aim of this study is to evaluate the clinical value of LIVERFAStTM as a non-invasive biopsy-proven surrogate assessment of non-alcoholic fatty liver disease. This is a cohort cross-sectional prospective, multi-centre study of an algorithm-based assessment of liver fibrosis, inflammatory activity (steatohepatitis) and steatosis compared to the histological assessment provided by liver biopsy performed in patients with suspected non-alcoholic steatohepatitis (NASH).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation, Liver Steatoses
Keywords
LIVERFASt, Liver biopsy, Liver Fibrosis, Liver Activity, Liver Steatosis, Non-invasive serum biomarker, Neural Network, Artificial Intelligence Machine Learning, Algorithm based test

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
241 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LIVERFASt validation
Arm Type
Experimental
Arm Description
blood draw for LIVERFASt
Intervention Type
Diagnostic Test
Intervention Name(s)
LIVERFASt
Intervention Description
blood draw
Primary Outcome Measure Information:
Title
Clinical performance of LIVERFASt Tests to determine liver fibrosis scores and staging compared with Liver Biopsy in patients with presumed Non-Alcoholic Fatty Liver Disease (NAFLD).
Description
Primary: Clinical performance of the LIVERFASt Fibrosis score using the results of five serum biomarkers (A2M, Haptoglobin, ApoA1, Total Bilrubin and GGT) for the over-all diagnostic of liver fibrosis (F0, F1, F2, F3 and F4 stages) using Binary and Non-Binary-Area Under the ROC curve
Time Frame
12 months
Title
Clinical performance of LIVERFASt Tests to determine inflammatory activity scores and staging compared with Liver Biopsy in patients with presumed Non-Alcoholic Fatty Liver Disease (NAFLD).
Description
Clinical performance of the LIVERFASt Activity scores using the results of six serum biomarkers (A2M, Haptoglobin, ApoA1, Total Bilrubin, GGT and ALT) for the over-all diagnostic of inflammatory activity (A0, A1, A2, A3 and A4 grades) using Binary and Non-Binary-Area Under the ROC curve
Time Frame
12 months
Title
Clinical performance of LIVERFAStTM Tests to determine steatosis grading compared with Liver Biopsy in patients with presumed Non-Alcoholic Fatty Liver Disease (NAFLD).
Description
Clinical performance of the LIVERFAstTM Steatosis grading tests using the results of ten serum biomarkers (A2M, Haptoglobin, ApoA1, Total Bilrubin, GGT, ALT, AST, Triglyceride, Cholesterol and Fasting Blood Glucose) for the over-all diagnostic of steatosis (S0, S1, S2 and S3), using Binary and Non-Binary-Area Under the ROC curve
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Clinical performance evaluation of the LIVERFASt Tests to evaluate and measure the definition of NAFLD based on fibrosis staging (F0, F1, F2, F3 and F4), inflammatory activity (A0, A1, A2, A3 and A4) and steatosis grading (S0, S1, S2, and S3).
Description
Secondary 200 adult men and women who are between the ages of 18-80 years old patients who have undergone liver biopsy with suspected non-alcoholic fatty liver disease within six (6) months of the enrollment and have undergone blood sampling for LIVERFASt testing using the generated results of ten serum biomarkers, namely: A2M, Haptoglobin, ApoA1, Total Bilrubin, GGT, ALT, AST, Triglyceride, Cholesterol and Fasting Blood Glucose, for the over-all diagnosis of fibrosis (F0, F1 to F4), activity (A0, A1 to A4) and steatosis (S0, S1 to S3). Performance (Bin-AUROC) of the LIVERFASt using the results of the combination of the ten biomarkers for the NAFLD definitions of NAFL, NASH and significant NASH (>S1≥A2≥F2)
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • Consenting patients with suspected NAFLD (by any means) having had undergone liver biopsy as part as their routine management, simultaneously or within six months from the day of blood sampling for LIVERFAStTM test. Aged 18 to 80 years old, inclusive Male or Female from any ethnicity Willing to undergo blood sampling for LIVERFAStTM testing after 6 to 12 hours fasting Willing to allow histological lecture by a pathologist for NASH-CRN and SAF scoring systems analysis of the liver biopsy Willing and able to allow access to requested data and who were informed and signed the consent form. Exclusion Criteria: • Inability to provide informed consent Patients who may be uncooperative with the sample collection procedures History of known Severe coagulopathy History of known Hepatic abscess Renal failure undergoing dialysis (GFR<45) History of Malignancy in the past 2 years Previous liver transplantation Suffering with a terminal illness or any other conditions or diseases that the investigator considers inappropriate for study participation Secondary causes of hepatic fat accumulation such as significant alcohol consumption, long-term use of a steatogenic medication, () Ongoing or recent significant alcohol consumption defined as >21 standard drinks on average per week in men and >14 standard drinks on average per week in women.8 Approximately 10 g of alcohol equals one 'drink' unit. One unit equals 1 ounce of distilled spirits, one 12-oz beer, or one 4-oz glass of wine. Total parenteral nutrition within 3 months of interview Short bowel syndrome History of gastric or jejunoileal bypass preceding the diagnosis of NAFLD. Bariatric surgery performed concomitant with or following the diagnosis of NAFLD does not exclude enrollment of patients. History of biliopancreatic diversion Evidence of advanced liver disease defined as a Child-Pugh-Turcotte score of equal to or greater than 10 Evidence of chronic hepatitis B as marked by the presence of HBsAg in serum (patients with isolated antibody to hepatitis B core antigen, anti-HBc, are not excluded) Evidence of chronic hepatitis C as marked by the presence of anti-HCV and HCV RNA in serum; patients with anti-HCV with PCR negative should not be excluded Low alpha-1-antitrypsin level and ZZ phenotype (both determined at the discretion of the investigator) History of Wilson's disease Known glycogen storage disease Known dysbetalipoproteinemia Known phenotypic hemochromatosis (determined at the discretion of the investigator) History of primary biliary cholangitis (PBC)/primary biliary sclerosis (PSC) Hepatic vascular lesions (determined at the discretion of the investigator) History of liver liver granulomas sarcoidosis, and infectious diseases such as tuberculosis) Congenital hepatic fibrosis, polycystic liver disease Other metabolic/congenital liver disease Evidence of systemic infectious disease Known HIV positive Disseminated or advanced extrahepatic malignancy Conditions that could interfere with LIVERFASt parameters and could lead to risk of false positive/ false negative results: Drug induced liver-injury (DILI), acute alcoholic hepatitis Acute inflammatory syndrome or sepsis Active drug use or dependence that, in the opinion of the study investigator, would interfere with adherence to study requirements
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ronald Quiambao, MD
Organizational Affiliation
Fibronostics USA, Inc
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Imtiaz Alam, MD
Organizational Affiliation
Ohio Gastroenterology and Liver Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sven Henrichwark
Organizational Affiliation
Fibronostics USA, Inc
Official's Role
Study Chair
Facility Information:
Facility Name
Henry Ford Health System
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
St. Louis University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63103
Country
United States
Facility Name
Northwell Health, Inc
City
Manhasset
State/Province
New York
ZIP/Postal Code
11030
Country
United States
Facility Name
GCGA Physicians, LLC
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45249
Country
United States
Facility Name
Methodist Health System Clinical Research Institute
City
Dallas
State/Province
Texas
ZIP/Postal Code
75203
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Houston Methodist Research Institute
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Liver Associates of Texas, P.A.
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD.

We'll reach out to this number within 24 hrs